COVID-19 CRO SERVICES

SARS-CoV-2 infection induces greater disease severity in the Physiogenex free-choice diet-induced obese NASH/MASH hamster – a metabolic comorbidities model of COVID-19

The devastating pandemic of COVID-19 (coronavirus disease 2019) is dramatically affecting every country on Earth, with millions of deaths and global economy turndown.

Obesity, type 2 diabetes and related comorbidities like NASH/MASH and heart failure are associated with the most severe forms of COVID-19 seen in humans. Therefore, preclinical animal models are urgently needed to validate therapies for obese/type 2 patients.

In collaboration with the Institut Pasteur de Lille, Physiogenex now delivers a unique metabolic comorbidities model infected with SARS-CoV-2:

the free choice diet-induced obese NASH/MASH hamster – a metabolic comorbidities model of COVID-19

•To see how you could move forward quickly with your drug candidate targeting COVID-19, check the model description below:

•If you wish to first evaluate your drug candidates on SARS-CoV-2 using in vitro assays or normal hamsters in vivo, please contact us below: